Decibel up after Regeneron extends collaboration period

Decibel Therapeutics

22/11/2021 15:15

** Shares of gene therapy developer  DBTX.O  rise 2% to
$7.60
    ** Regeneron  REGN.O  extends research term of its
collaboration with co to discover and develop gene therapies for
hearing loss (https://refini.tv/3cC01pz)
    ** Research term will be extended to Nov. 15, 2023
    ** DBTX to receive $10 mln payment from REGN in Q4 of 2022
for the extension 
    ** Under the collaboration launched in 2017, DBTX is
developing three gene therapy programs with REGN targeting
congenital, monogenic hearing loss 
    ** DBTX says collaboration gene therapy DB-OTO for treatment
of Otoferlin-mediated hearing loss set to enter early stage
clinical trials in 2022

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))